Ovid Therapeutics Inc. Banner Image

Ovid Therapeutics Inc. has reached its limit for free report views

Work for Ovid Therapeutics Inc.? Upgrade Your Profile and unlock all your annual reports.

Ovid Therapeutics Inc.

  • Ticker OVID
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Ovid Therapeutics Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment ofMore Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs).
Ovid Therapeutics Inc.

Most Recent Annual Report

Ovid Therapeutics Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Ovid Therapeutics Inc. has reached its limit for free report views.

Older/Archived Annual Reports